Fusion Pharmaceuticals Inc. Business Finance Contracts & Agreements
21 Contracts & Agreements
- Investor Rights Agreements (1 contract)
- Loan Agreements (3)
- Purchase Agreements (9)
- Registration Rights Agreements (3)
- Share Agreements (3)
- Underwriting Agreements (1)
- Warrant Agreements (1)
- Registration Rights Agreement, dated May 10, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on May 11, 2023)
- Securities Purchase Agreement, dated May 10, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on May 11, 2023)
- Registration Rights Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 14, 2023)
- Securities Purchase Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 14, 2023)
- Option and Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and RadioMedix, Inc., dated November 14, 2022 (Filed With SEC on February 14, 2023)
- Registration Rights Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 13, 2023)
- Securities Purchase Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 13, 2023)
- Option and Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and RadioMedix, Inc., dated November 14, 2022 (Filed With SEC on February 13, 2023)
- Second Amendment to Loan and Security Agreement, dated as of September 21, 2022, by and between Oxford Finance LLC and the Company (Filed With SEC on November 8, 2022)
- Consent and First Amendment to Loan and Security Agreement, dated as of August 23, 2022, by and between Oxford Finance LLC and the Company (Filed With SEC on November 8, 2022)
- Loan and Security Agreement, dated as of April 4, 2022, by and between Oxford Finance LLC and the Company (Filed With SEC on August 9, 2022)
- Amendment No. 2 to Asset Purchase Agreement, dated February 8, 2021, by and between Rainier Therapeutics, Inc. and the Company (Filed With SEC on March 25, 2021)
- Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and Ipsen Pharma SAS, dated March 1, 2021 (Filed With SEC on March 2, 2021)
- Amendment No. 1 to Asset Purchase Agreement, dated October 8, 2020, by and between Fusion Pharmaceuticals Inc. and Rainier Therapeutics, Inc (Filed With SEC on November 10, 2020)
- 2020 Employee Share Purchase Plan (Filed With SEC on June 22, 2020)
- Form of Specimen Common Share Certificate (Filed With SEC on June 22, 2020)
- Form of Underwriting Agreement (Filed With SEC on June 22, 2020)
- Asset Purchase Agreement, dated as of March 10, 2020, by and between Rainier Therapeutics, Inc., Fortis Advisors LLC and the Registrant (Filed With SEC on June 5, 2020)
- Form of Class B Preferred Share Purchase Warrants (Filed With SEC on June 5, 2020)
- Form of Class B Preferred Exchangeable Share Purchase Warrant (Filed With SEC on June 5, 2020)
- Amended and Restated Investors Rights Agreement among the Registrant and certain of its shareholders, dated March 25, 2019 (Filed With SEC on June 5, 2020)
